2022-10-062022-10-062007-08Ali, R. vd. (2007). "Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moon". Lekukemia Research, 31(8), 1153-1155.0145-21261873-5835https://doi.org/10.1016/j.leukres.2006.07.017https://www.sciencedirect.com/science/article/pii/S0145212606002700http://hdl.handle.net/11452/28992eninfo:eu-repo/semantics/closedAccessProgressionPlasmacytomaTherapyPlasmacytomaAgedAntineoplastic agentsBoronic acidsFemaleHumansMultiple myelomaPyrazinesTreatment outcomeLetter0002480620000192-s2.0-34249871670115331816945413OncologyHematologyPlasmacytoma; Multiple Myeloma; Pleura EffusionDisease courseAgedAllogeneic stem cell transplantationAutologous stem cell transplantationBackacheBone marrow biopsyCancer relapseCancer stagingCase reportCombination chemotherapyComputer assisted tomographyDiarrheaFemaleAntineoplastic agentHistopathologyPrednisoneHumanVincristineBoronic acid derivativeBortezomibHuman tissuePyrazine derivativeLetterAlpha2b interferonPlasmacytomaBortezomibMultiple cycle treatmentMultiple myelomaNeuropathyNeutropeniaPathologyPriority journalDexamethasonePneumoniaPlasmacytomaDoxorubicinMelphalanRadiodiagnosisRemissionThrombocytopeniaTreatment outcomeMultiple myeloma